CN104906160A - 一种灯盏细辛提取物的肠溶制剂 - Google Patents
一种灯盏细辛提取物的肠溶制剂 Download PDFInfo
- Publication number
- CN104906160A CN104906160A CN201510269499.0A CN201510269499A CN104906160A CN 104906160 A CN104906160 A CN 104906160A CN 201510269499 A CN201510269499 A CN 201510269499A CN 104906160 A CN104906160 A CN 104906160A
- Authority
- CN
- China
- Prior art keywords
- herba erigerontis
- enteric
- preparation
- erigerontis extract
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 66
- 241001013934 Erigeron breviscapus Species 0.000 title abstract description 11
- 239000000284 extract Substances 0.000 claims description 67
- 239000000463 material Substances 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 230000001476 alcoholic effect Effects 0.000 claims description 13
- 239000002775 capsule Substances 0.000 claims description 11
- 239000007962 solid dispersion Substances 0.000 claims description 9
- 238000005507 spraying Methods 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 8
- 241000758794 Asarum Species 0.000 claims description 6
- 239000003463 adsorbent Substances 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 6
- 239000003480 eluent Substances 0.000 claims description 6
- 238000010828 elution Methods 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 239000012567 medical material Substances 0.000 claims description 6
- 239000004005 microsphere Substances 0.000 claims description 6
- 238000004064 recycling Methods 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 239000011347 resin Substances 0.000 claims description 6
- 229920005989 resin Polymers 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 29
- 239000012530 fluid Substances 0.000 abstract description 13
- 238000004090 dissolution Methods 0.000 abstract description 9
- 230000002496 gastric effect Effects 0.000 abstract description 9
- 210000001156 gastric mucosa Anatomy 0.000 abstract description 6
- 230000000968 intestinal effect Effects 0.000 abstract description 6
- 230000000638 stimulation Effects 0.000 abstract description 5
- 238000005516 engineering process Methods 0.000 abstract description 4
- 239000004615 ingredient Substances 0.000 abstract description 4
- 150000007965 phenolic acids Chemical class 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 22
- 239000000243 solution Substances 0.000 description 18
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 16
- 239000000203 mixture Substances 0.000 description 13
- 229960004756 ethanol Drugs 0.000 description 12
- 238000002156 mixing Methods 0.000 description 11
- 238000003756 stirring Methods 0.000 description 10
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 9
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 9
- 229920002472 Starch Polymers 0.000 description 8
- 229910021529 ammonia Inorganic materials 0.000 description 8
- 238000007796 conventional method Methods 0.000 description 8
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 229960003943 hypromellose Drugs 0.000 description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 6
- 239000008108 microcrystalline cellulose Substances 0.000 description 6
- -1 reflux Substances 0.000 description 6
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 5
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 5
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 5
- 238000001694 spray drying Methods 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 3
- 229920003139 Eudragit® L 100 Polymers 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 238000000889 atomisation Methods 0.000 description 3
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229960000935 dehydrated alcohol Drugs 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000012982 microporous membrane Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000007939 sustained release tablet Substances 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 2
- VEYIMQVTPXPUHA-UHFFFAOYSA-N 3-hydroxypyran-4-one Chemical compound OC1=COC=CC1=O VEYIMQVTPXPUHA-UHFFFAOYSA-N 0.000 description 2
- 239000004925 Acrylic resin Substances 0.000 description 2
- 102220487426 Actin-related protein 2/3 complex subunit 3_K15M_mutation Human genes 0.000 description 2
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 206010048768 Dermatosis Diseases 0.000 description 2
- 241000132521 Erigeron Species 0.000 description 2
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 2
- 240000003183 Manihot esculenta Species 0.000 description 2
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 2
- 239000008118 PEG 6000 Substances 0.000 description 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- DJSISFGPUUYILV-UHFFFAOYSA-N UNPD161792 Natural products O1C(C(O)=O)C(O)C(O)C(O)C1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 2
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 2
- ZXVOCOLRQJZVBW-UHFFFAOYSA-N azane;ethanol Chemical compound N.CCO ZXVOCOLRQJZVBW-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- NPLTVGMLNDMOQE-UHFFFAOYSA-N carthamidin Natural products C1=CC(O)=CC=C1C1OC2=CC(O)=C(O)C(O)=C2C(=O)C1 NPLTVGMLNDMOQE-UHFFFAOYSA-N 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012738 dissolution medium Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 229950005770 hyprolose Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000005453 pelletization Methods 0.000 description 2
- LGRFSURHDFAFJT-UHFFFAOYSA-N phthalic anhydride Chemical compound C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- DJSISFGPUUYILV-ZFORQUDYSA-N scutellarin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-ZFORQUDYSA-N 0.000 description 2
- 229930190376 scutellarin Natural products 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 230000003156 vasculitic effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 229920003135 Eudragit® L 100-55 Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000567534 Pulicaria Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical group CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种灯盏细辛提取物肠溶制剂,肠溶制剂是用灯盏细辛提取物和肠溶制剂药用辅料制成,其组成物及重量份为灯盏细辛提取物1份,辅料2~19份;以灯盏细辛乙醇提取物为原料,添加辅料后经肠溶制剂技术制成灯盏细辛肠溶制剂;实验结果表明,所述肠溶制剂在人工胃液中的溶出度低于5%,在人工肠液中崩解释放;本发明制剂可有效避免灯盏细辛中酚酸类成分对胃黏膜的刺激,并且工艺操作简单,适合产业化生产。
Description
技术领域
本发明涉及的是一种中药的新剂型,具体涉及一种口服灯盏细辛提取物肠溶制剂,属于医药制剂领域。
背景技术
灯盏细辛始载于《滇南本草》,为菊科飞蓬属植物短亭飞蓬(Erigeron breviscapas vant Hand Mass)全草,又称灯盏花,具有散寒解表、祛风除湿、活血化瘀、通络止痛、改善微循环等功效,临床上广泛用于治疗高血压、脑溢血、冠心病、心绞痛等病症,市场经济前景广阔,其药用价值也在不断开发中。现在灯盏细辛提取物不仅成为了有良好疗效的心脑血管的药品,也被开发成保健品使用[杨建文等:灯盏花保健酒及其制作方法;CN101307284A]。
目前,普通的灯盏细辛制剂直接在胃中崩解吸收,对胃黏膜刺激性较大,在临床使用过程中有病人反映长期使用可引起胃不适的副作用;这是由于灯盏细辛提取物中的有效成分不仅包括灯盏乙素等黄酮类成分,也包括焦袂康酸、原儿茶酸等酚酸类的化合物,若长期服用会造成胃损伤。若要长期服用灯盏细辛提取物的制剂进行慢性心脑血管疾病的预防和治疗,这样的胃刺激副作用不容忽视。
随着灯盏细辛药用价值的逐渐开发,其剂型的改变也多种多样。如201110391592.0中利用云南特色资源灯盏细辛研制开发的一种灯盏细辛提取物的无糖型口服制剂;200510055205.0的益脉康口腔崩解片系采用灯盏细辛浸膏为原料制成的口腔快速崩解制剂,用于治疗心脑血管系统疾病和周围神经病变的药物制剂;200510072048公开了一种以灯盏细辛提取物和基质为配方的灯盏细辛滴丸及其制备方法,用于治疗缺血性脑血管及脑出血后遗瘫痪,眼底视网膜静脉阻塞,冠心病,血管炎性皮肤病,风湿病;200410079522.1公开了一种灯盏细辛有效成分提取物软胶囊及其制备方法,主要适用于心血管疾病及其后遗症、眼底视网膜静脉阻塞、血管炎性皮肤病、风湿病;200410079521.7公开了一种灯盏细辛有效成分提取物分散片及其制备方法,所含灯盏细辛有效成分提取物微分的重量百分比为10~80%。虽然上述所有剂型都属于口服型制剂,并直接经过胃肠道吸收,但均未涉及灯盏细辛肠溶制剂。
为保证良好疗效的同时减少不良反应,方便长期使用,可考虑开发为灯盏细辛肠溶制剂,而目前尚未有相关的专利和文献报道。
发明内容
本发明的目的是提供一种灯盏细辛提取物肠溶制剂,其是用灯盏细辛提取物和肠溶制剂药用辅料制成,其中灯盏细辛提取物为1份,辅料为2~19份,避免灯盏细辛在胃中溶解,克服不良反应,最大程度减少对胃黏膜产生的刺激,及其引起的不适,提高药物稳定性,改善其胃肠道的崩解和释放。
所述灯盏细辛提取物的制备方法如下:将干燥灯盏细辛药材粉碎,过16~20目筛,在粉碎的药材中添加药材质量10~15倍的质量百分比浓度为60%乙醇溶液,回流提取2~3次,每次30min,合并提取液,减压浓缩回收溶剂,浓缩液用水稀释,过滤,滤液上大孔吸附树脂,水洗脱至无色后,用质量百分比浓度为30%~95%的乙醇溶液洗脱,洗脱液体积为5~20倍柱体积;洗脱液浓缩,调节pH值至6.5,然后喷雾干燥,即得棕黄色灯盏细辛提取物。
所述灯盏细辛提取物肠溶制剂为肠溶固体分散体、肠溶胶囊、肠溶片或肠溶微球。
所述肠溶固体分散体是按常规方法制得,例如将灯盏细辛提取物1份、肠溶固体分散体载体1~3份、崩解剂2~6份,溶解在含有乙醇的氨水溶液中,混匀,喷雾干燥后制得,其中含有乙醇的氨水溶液是按体积百分比40~80%的比例在40℃~60℃下将乙醇添加到质量百分比浓度为0.3~1%的氨水溶液中混合而成。
其中肠溶固体分散体载体为醋酸纤维素酞酸酯、羟丙基纤维素酞酸酯、聚丙烯酸树脂或邻苯二甲酸醋酸纤维素;崩解剂交联羧甲基纤维素钠、交联聚维酮或羧甲基淀粉钠。
所述肠溶胶囊是按常规方法制得,例如将上述所制备的肠溶固体分散体干燥,过筛,常规方法制备颗粒或直接与药剂学常用辅料混匀装入普通胶囊;或将适量灯盏细辛提取物过筛,常规方法制粒或直接与药剂学常用辅料混匀后,装入肠溶胶囊。
所述肠溶片是按常规方法制得,例如将灯盏细辛提取物过60~100目筛,常规方法制粒,压制成片,药片再包肠溶衣;或取1份灯盏细辛提取物,加入0.5~10份骨架缓释材料、0.5~3.5份填充剂和适量润滑剂,采用湿法制粒压片或者干法直接压片。
其中骨架缓释材料为乙基纤维素、羟丙甲纤维素或羟甲基纤维素钠;填充剂为纤维素、淀粉、糊精;润滑剂为十二烷基硫酸盐。
所述肠溶微球是按常规方法制得,例如将灯盏细辛提取物、羟丙甲纤维素酞酸酯HP-55和乙醇按照体积比1:3-10:3-9的比例混合得到混合溶液,然后在20℃~30℃,300rpm~600rpm的搅拌条件下,将混合溶液注入十二烷基硫酸钠水溶液中,搅拌10~20min后补加30ml~60ml的十二烷基硫酸钠水溶液,继续搅拌待球形颗粒完全融化后,过滤,干燥制得,其中十二烷基硫酸钠水溶液为质量百分是0.3%的水溶液。
本发明相对于现有技术的优点和技术效果:
1、采用的制备方法简便,制备过程易于控制,制得的产品质量可控、稳定,且所得灯盏细辛制剂对胃黏膜无刺激性;
2、本发明制剂避免灯盏细辛在胃中溶解,克服不良反应,最大程度减少对胃黏膜产生的刺激,及其引起的不适,提高药物稳定性,改善其胃肠道的崩解和释放;
综上,采用上述处方、步骤及参数控制可得到灯盏细辛肠溶的各种剂型,可使减少灯盏细辛对胃黏膜的刺激,提高产品稳定性、有效成分的溶出及生物利用度。同时,该制备方法简单易行,技术对设备无特殊要求,适于大规模生产。
附图说明
图1为本发明灯盏细辛肠溶制剂人工胃液溶出曲线;
图2为本发明灯盏细辛肠溶制剂人工肠液溶出曲线。
具体实施方式
下面通过附图和实施例对本发明作进一步详细说明,但本发明保护范围不局限于所述内容,实施例中方法如无特殊说明均为常规方法,使用试剂如无特殊说明均为常规市售试剂。
实施例1:肠溶固体分散体的制备
灯盏细辛提取物 5g
邻苯二甲酸醋酸纤维素 15g
交联聚维酮 10g
(1)灯盏细辛提取物的制备方法如下:将干燥灯盏细辛药材粉碎,过20目筛,在粉碎的药材中添加药材质量10倍的质量百分比浓度为60%乙醇溶液,回流提取2次,每次30min,合并提取液,减压浓缩回收溶剂,浓缩液用水稀释,过滤,滤液上HPD-100型大孔吸附树脂,水洗脱至无色后,用质量百分比浓度为90%的乙醇溶液洗脱,洗脱液体积为10倍柱体积;洗脱液浓缩,调节pH值至6.5,然后喷雾干燥,即得棕黄色灯盏细辛提取物;
(2)将灯盏细辛提取物5g、邻苯二甲酸醋酸纤维素15g、交联聚维酮10g,溶解在含有乙醇的氨水溶液中,混匀,喷雾干燥,喷雾干燥参数为:进口温度50℃,喷雾速度2ml/min,喷雾压力为5bar,干燥后得肠溶固体分散体,其中含有乙醇的氨水溶液是按体积百分比3:2的比例在50℃下将乙醇添加到质量百分比浓度为0.4%的氨水溶液中混合而成。
实施例2:肠溶固体分散体的制备
灯盏细辛提取物 5g
Eudragit L100(载体) 10g
羟丙甲纤维素 1.5g
(1)灯盏细辛提取物的制备方法如下:将干燥灯盏细辛药材粉碎,过16目筛,在粉碎的药材中添加药材质量15倍的质量百分比浓度为60%乙醇溶液,回流提取3次,每次30min,合并提取液,减压浓缩回收溶剂,浓缩液用水稀释,过滤,滤液上HPD-100型大孔吸附树脂,水洗脱至无色后,用质量百分比浓度为50%的乙醇溶液洗脱,洗脱液体积为15倍柱体积;洗脱液浓缩,调节pH值至6.5,然后喷雾干燥,即得棕黄色灯盏细辛提取物;
(2)取10g辅料Eudragit L100于适量二次蒸馏水中自然溶胀1h,另外将5g灯盏细辛提取物以适量二次蒸馏水溶解,然后将其加入到已经溶胀好的Eudragit L100中,同时加入预先溶解好的释放调节剂羟丙甲纤维素1.5g于上述器皿中;剧烈搅拌,超声混合并分散20min。取出后冷冻干燥12h,然后真空干燥24h;取出研磨并放置干燥处保存。
实施例3:肠溶胶囊的制备
灯盏细辛提取物 5g
β-环糊精 7.5g
羧甲基淀粉钠 1.5g
聚丙烯酸树脂L100-55 15g
微晶纤维素 50g
(1)灯盏细辛提取物的制备方法如下:将干燥灯盏细辛药材粉碎,过18目筛,在粉碎的药材中添加药材质量12倍的质量百分比浓度为60%乙醇溶液,回流提取3次,每次30min,合并提取液,减压浓缩回收溶剂,浓缩液用水稀释,过滤,滤液上HPD-100型大孔吸附树脂,水洗脱至无色后,用质量百分比浓度为35%的乙醇溶液洗脱,洗脱液体积为5倍柱体积;洗脱液浓缩,调节pH值至6.5,然后喷雾干燥,即得棕黄色灯盏细辛提取物;
(2)将灯盏细辛提取物5g、β-环糊精7.5g溶解乙醇氨水溶液中(按体积比2:3的比例在40℃下将无水乙醇添加到浓度为0.3%的氨水溶液中混合制得),将上述混合液用喷雾干燥法进行干燥,其中喷雾干燥参数为:进口温度40℃,喷雾速度2ml/min,喷雾压力为1bar,最后收集干燥好的灯盏细辛环糊精包和物。称取羧甲基淀粉钠1.5g、聚丙酸树脂L100-55 15g,加入到70ml40%的乙醇中,40℃搅拌溶解,保温,旋转蒸发并干燥,过80目筛,再与50g微晶纤维素混匀,装入普通胶囊中,得到灯盏细辛肠溶胶囊。
实施例4:肠溶胶囊的制备
灯盏细辛提取物 5g
α-环糊精 10g
Eudragit (L30D-55) 10g
滑石粉 2g
PEG6000 1g
(1)灯盏细辛提取物的制备方法如下:将干燥灯盏细辛药材粉碎,过18目筛,在粉碎的药材中添加药材质量12倍的质量百分比浓度为60%乙醇溶液,回流提取3次,每次30min,合并提取液,减压浓缩回收溶剂,浓缩液用水稀释,过滤,滤液上HPD-100型大孔吸附树脂,水洗脱至无色后,用质量百分比浓度为35%的乙醇溶液洗脱,洗脱液体积为20倍柱体积;洗脱液浓缩,调节pH值至6.5,然后喷雾干燥,即得棕黄色灯盏细辛提取物;
(2)将灯盏细辛提取物5g、α-环糊精10g溶解于乙醇氨水溶液中(按体积比3:2的比例在40℃下将无水乙醇添加到浓度为0.3%的氨水溶液中混合制得),混合均匀后用喷雾干燥法进行干燥,其中喷雾干燥参数为:进口温度35℃,喷雾速度2ml/min,喷雾压力为1bar,收集灯盏细辛环糊精包和物干燥备用。取Eudragit (L30D-55)10g,滑石粉2g,PEG6000 1g在50%乙醇中溶解并混合均匀,超声15min制成肠溶包衣。将上述灯盏细辛环糊精包和物装入普通胶囊,然后放入流化床中,用肠溶包衣液进行包衣。工艺条件:进液速度4ml/min,进口温度 35℃,出口温度30℃,喷嘴压力0.3MPa,干燥空气流量300m3/h,最后氮气密封保存肠溶胶囊。
实施例5:肠溶片的制备
灯盏细辛提取物 2g
羟丙基β-环糊精 4g
乳糖 4g
微晶纤维素 2g
甲基纤维素 2g
交联聚维酮 3g
羧甲基淀粉钠 3g
微粉硅胶 0.5份
羟丙甲纤维素酞酸酯和醋酸纤维素酞酸 0.5份
(1)灯盏细辛提取物的制备方法同实施例1;
(2)在质量百分比浓度为70%的乙醇介质中,将灯盏细辛提取物2g与羟丙基β-环糊精4g反应,将所得溶液经微孔滤膜过滤至澄清,从混合物中分离出包和物;将灯盏细辛包和物粉碎过100目筛,将其与辅料粉碎过80目筛;准确称取乳糖4g,微晶纤维素2g,甲基纤维素2g,交联聚维酮3g,羧甲基淀粉钠3g,混合均匀,3%聚乙烯吡咯烷酮95%的乙醇溶液制粒,18目筛整粒,40℃干燥。加入1g微粉硅胶,混合均匀,过18目筛,分为20片压片,羟丙甲纤维素酞酸酯和醋酸纤维素酞酸包肠溶衣,即得。
实施例6:肠溶片的制备
灯盏细辛提取物 2.0g
木薯淀粉 0.6g
羟丙甲纤维素 0.2g
玉米淀粉 4.0g
羧甲淀粉钠 1.0g
硬脂酸镁 0.2g
羟丙纤维素 0.8g
(1)灯盏细辛提取物的制备方法同实施例1;
(2)首先用冷二次蒸馏水将0.6g木薯淀粉稀释成混悬液,另用热二次蒸馏水将0.2g羟丙甲纤维素快速搅匀并倒入上述混悬液中,用以制备粘合剂。然后将2g灯盏细辛提取物和4g玉米淀粉倒入湿法混合制粒机中,混合均匀并倒入上述粘合剂搅拌2min制成湿颗粒。用高效沸腾干燥机干燥,相关参数:进风温度105~115℃,出风温度55~60℃,干燥至湿颗粒水分含量为5%后用多功能整粒机筛整粒。将1g羧甲淀粉钠、0.2g硬脂酸镁、0.8g羟丙纤维素混合,再将上述颗粒均衡加入混合机中混合20min,真空干燥24h即得。
实施例7:肠溶骨架缓释片的制备
灯盏细辛提取物 20.0g
羟丙甲纤维素K4M 4.0g
羟丙甲纤维素K15M 8.0g
海藻酸钠 4.0g
乳糖 10.0g
微晶纤维素 8.0g
硬脂酸镁 2.0g
碳酸氢钠 2.0g
(1)灯盏细辛提取物的制备方法同实施例1;
(2)称取20g灯盏细辛提取物及4g K4M、8g K15M、4g海藻酸钠、10g乳糖、8g微晶纤维素和2g碳酸氢钠,分别粉碎过100目筛混合,再加入2g硬脂酸镁混匀后分为50份直接压片即得。
实施例8:肠溶骨架缓释片的制备
灯盏细辛提取物 1.0g
壳聚糖 0.5g
淀粉 0.5g
乙基纤维素 2.0g
十二烷基硫酸钠 0.3g
滑石粉 0.2g
(1)灯盏细辛提取物的制备方法同实施例1;
(2)准确称取灯盏细辛1g,壳聚糖0.5g,淀粉0.5g并混匀,加入适量聚乙二醇后制粒压片干燥。用10倍(质量)95%乙醇将2g乙基纤维素浸泡10小时,搅拌使其溶解完全后,加入十二烷基硫酸钠0.3g和滑石粉0.2g,搅拌混合均匀,过筛得薄膜衣液;将上述制得的压片表面包薄膜衣,即得灯盏细辛骨架肠溶缓释片。
实施例9:肠溶微球的制备
灯盏细辛提取物 1g
羟丙甲纤维素酞酸酯HP-55 5g
(1)灯盏细辛提取物的制备方法同实施例2;
(2)将1g灯盏细辛提取物和5g HP-55溶解于无水乙醇和二氯甲烷溶剂4.0ml中,形成有机液;在25℃和500rpm搅拌条件下将此有机液注入0.3%十二烷基硫酸钠水溶液42ml中,继续搅拌,再补加同量水溶液;继续搅拌至球形颗粒固化,过滤,干燥,收集肠溶微球。
实施例10:肠溶微球的制备
灯盏细辛提取物 1g
邻苯二甲酸羟丙基甲基纤维素 2g
微粉硅胶 2g
(1)灯盏细辛提取物的制备方法同实施例3;
(2)称取2g邻苯二甲酸羟丙基甲基纤维素,向其中加入50ml的80%乙醇,制得肠溶材料溶液。精密称取1g灯盏细辛提取物并加入到上述肠溶材料中溶解,再加入蓖麻油2ml搅拌均匀,然后加入微粉硅胶2g混合均匀。喷雾干燥,工作参数为进风温度80℃,出风温度60℃,加料速度20ml/min,气流量600nl/h,即得。
实验例11:溶出度的测定
以人工胃液(pH 1.0)500ml为溶剂,温度(37±1)℃,转速为100rpm。将肠溶制剂投入杯中,自样品与溶出介质接触时开始计时,分别于10、20、30、45、60、90、120min采样3ml,0.8μm微孔滤膜过滤,得到溶出液样品,并立刻补充同体积等温新鲜人工胃液介质。2h后及时把样品转入人工肠液(pH 6.8),以同等条件溶出,自样品与溶出介质接触时开始计时,分别于10、20、30、45、60、90、120min采样3ml,0.8μm微孔滤膜过滤,得到溶出液样品,并立刻补充同体积等温新鲜人工肠液介质,每个取样操作在25s内完成并用紫外分光光度计进行检测,计算溶出度。
累计溶出百分量计算如下:
式中Vs为取样体积,Vr为介质体积,C为样品浓度,n为取样次数,W为灯盏细辛肠溶制剂的含药量。
表1:实施例1-10灯盏细辛肠溶制剂人工胃液溶出度(%)
。
表2:实施例1-10灯盏细辛肠溶制剂人工肠液溶出度(%)
。
上述实验结果表明,所得灯盏细辛肠溶制剂达到了预期的释药效果,即几乎不在胃液中崩解,减少了药物对胃部的刺激作用。同时,在肠液中的溶出度几乎可以达到100%,不影响药效作用(见图1、2)。
Claims (3)
1.一种灯盏细辛提取物肠溶制剂,其特征在于:肠溶制剂是用灯盏细辛提取物和肠溶制剂药用辅料制成,其组成物及重量份为灯盏细辛提取物1份,辅料2~19份。
2.根据权利要求1所述的灯盏细辛提取物肠溶制剂,其特征在于:灯盏细辛提取物的制备方法如下:将干燥灯盏细辛药材粉碎,过16~20目筛,在粉碎的药材中添加药材质量10~15倍的质量百分比浓度为60%乙醇溶液,回流提取2~3次,每次30min,合并提取液,减压浓缩回收溶剂,浓缩液用水稀释,过滤,滤液上大孔吸附树脂,水洗脱至无色后,用质量百分比浓度为30%~95%的乙醇溶液洗脱,洗脱液体积为5~20倍柱体积;洗脱液浓缩,调节pH值至6.5,然后喷雾干燥,即得棕黄色灯盏细辛提取物。
3.根据权利要求1或2所述的灯盏细辛提取物肠溶制剂,其特征在于:肠溶制剂为肠溶固体分散体、肠溶胶囊、肠溶片或肠溶微球。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510269499.0A CN104906160B (zh) | 2015-05-25 | 2015-05-25 | 一种灯盏细辛提取物的肠溶制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510269499.0A CN104906160B (zh) | 2015-05-25 | 2015-05-25 | 一种灯盏细辛提取物的肠溶制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104906160A true CN104906160A (zh) | 2015-09-16 |
CN104906160B CN104906160B (zh) | 2018-07-24 |
Family
ID=54075879
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510269499.0A Active CN104906160B (zh) | 2015-05-25 | 2015-05-25 | 一种灯盏细辛提取物的肠溶制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104906160B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107982222A (zh) * | 2017-12-01 | 2018-05-04 | 李文刚 | 灯盏花素冻干肠溶片或肠溶胶囊的制备方法 |
CN112618504A (zh) * | 2020-11-19 | 2021-04-09 | 云南生物谷药业股份有限公司 | 含有灯盏细辛提取物和冰片的药物组合物及其制备方法 |
CN116966159A (zh) * | 2023-08-29 | 2023-10-31 | 河南省纳普生物技术有限公司 | 一种含地黄提取物的降糖制剂及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1543973A (zh) * | 2003-11-13 | 2004-11-10 | 上海现代药物制剂工程研究中心有限公 | 灯盏花素高效缓释组合物及其颗粒胶囊 |
CN1733071A (zh) * | 2004-07-30 | 2006-02-15 | 贵阳云岩西创药物科技开发有限公司 | 一种治疗心脑血管疾病的中药制剂及其制备方法 |
CN1739537A (zh) * | 2004-08-26 | 2006-03-01 | 张红军 | 灯盏花素环糊精包合物及其制剂 |
CN1853660A (zh) * | 2004-08-13 | 2006-11-01 | 贵阳云岩西创药物科技开发有限公司 | 灯盏细辛制剂及其制备方法 |
CN101185653A (zh) * | 2006-10-16 | 2008-05-28 | 复旦大学 | 灯盏花素口服组合物及其制备方法 |
-
2015
- 2015-05-25 CN CN201510269499.0A patent/CN104906160B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1543973A (zh) * | 2003-11-13 | 2004-11-10 | 上海现代药物制剂工程研究中心有限公 | 灯盏花素高效缓释组合物及其颗粒胶囊 |
CN1733071A (zh) * | 2004-07-30 | 2006-02-15 | 贵阳云岩西创药物科技开发有限公司 | 一种治疗心脑血管疾病的中药制剂及其制备方法 |
CN1853660A (zh) * | 2004-08-13 | 2006-11-01 | 贵阳云岩西创药物科技开发有限公司 | 灯盏细辛制剂及其制备方法 |
CN1739537A (zh) * | 2004-08-26 | 2006-03-01 | 张红军 | 灯盏花素环糊精包合物及其制剂 |
CN101185653A (zh) * | 2006-10-16 | 2008-05-28 | 复旦大学 | 灯盏花素口服组合物及其制备方法 |
Non-Patent Citations (1)
Title |
---|
杨明等: "《药剂学》", 31 August 2014 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107982222A (zh) * | 2017-12-01 | 2018-05-04 | 李文刚 | 灯盏花素冻干肠溶片或肠溶胶囊的制备方法 |
CN112618504A (zh) * | 2020-11-19 | 2021-04-09 | 云南生物谷药业股份有限公司 | 含有灯盏细辛提取物和冰片的药物组合物及其制备方法 |
CN112618504B (zh) * | 2020-11-19 | 2022-08-16 | 云南生物谷药业股份有限公司 | 含有灯盏细辛提取物和冰片的药物组合物及其制备方法 |
CN116966159A (zh) * | 2023-08-29 | 2023-10-31 | 河南省纳普生物技术有限公司 | 一种含地黄提取物的降糖制剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN104906160B (zh) | 2018-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101278932B (zh) | 含有扎托布洛芬的缓释药物组合物及其制备方法与应用 | |
CN102245171A (zh) | 缓释微粒及其制备方法 | |
JPS6410494B2 (zh) | ||
JP2016539955A (ja) | 薬物組成物、及びその製造方法、並びに使用 | |
JP2005538121A (ja) | 遅延放出抗ウイルス物質産物、その使用法と製剤 | |
CN108042503B (zh) | 一种高效的炎琥宁肠溶片及制备方法 | |
CN104906160A (zh) | 一种灯盏细辛提取物的肠溶制剂 | |
CN107982241B (zh) | 一种炎琥宁肠溶制剂及制备方法 | |
CN101773498A (zh) | 一种含有非布司他的口服缓控释制剂及其制备方法 | |
CN1771913B (zh) | 用乳化溶剂扩散法制备掩味微球的制备方法 | |
CN101623269A (zh) | 口服缓释给药的颗粒 | |
CN110075082A (zh) | 一种恩诺沙星速释微丸及其制备方法 | |
CN100486568C (zh) | 洛索洛芬钠缓释制剂 | |
CN107982240B (zh) | 一种可精准溶出的炎琥宁肠溶颗粒及制备方法 | |
CN102038642A (zh) | 一种银杏内酯b固体分散体及其制备方法 | |
CN103405395B (zh) | 匹可硫酸钠肠溶片及其制备方法 | |
CN112569190B (zh) | 一种白头翁皂苷b4的口服给药制剂及其制备方法 | |
CN103655585A (zh) | 一种天麻素控释制剂及其制备方法 | |
CN101879139A (zh) | 一种治疗消化性疾病的肠溶制剂及其制备方法 | |
CN102552139A (zh) | 一种原花青素自乳化体系组合物及其应用 | |
CN106606488A (zh) | 一种鲁格列净药物组合物及其制备方法 | |
CN101244068B (zh) | 雪胆素缓释制剂 | |
CN101081227B (zh) | 甘草酸二铵的组合物 | |
CN108042583A (zh) | 一种银杏叶片生产过程 | |
CN1857482A (zh) | 一种清热燥湿,杀虫止痒的中药复方制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |